Supplementary Methods from Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline &lt;i&gt;BRCA1/2&lt;/i&gt; Mutations and Selected Sporadic Cancers